Cell-Penetrating Peptides Boost Antimalarial Drug Potency But Destroy Red Blood Cells — A Cautionary Finding

Multiple chloroquine-TP10 and primaquine-TP10 conjugates were synthesized and tested for antiplasmodial activity against P. falciparum. Hemolytic activity was assessed using red blood cell lysis assays. Fluorescence microscopy and flow cytometry were used to visualize and quantify conjugate binding to erythrocyte membranes. A panel of different cell-penetrating peptides was tested to determine if the effect was specific to TP10.

Malaria kills over 600,000 people annually, and drug resistance is a growing threat. Cell-penetrating peptides were seen as a promising strategy to enhance drug delivery into infected red blood cells. This study provides a critical safety warning that could prevent wasted research effort and, more importantly, prevent potential harm if such conjugates were advanced without proper hemolysis testing. It also highlights a broader principle: peptide-drug conjugates can have emergent toxicities that neither component shows alone.

Cell-penetrating peptides (CPPs) have been celebrated as versatile delivery vehicles for over two decades, successfully transporting nucleic acids, proteins, imaging agents, and small molecules across cell membranes. This study provides an important counterexample — not all peptide-drug combinations are safe. For malaria specifically, the problem is fundamental: aminoquinoline drugs target parasites inside red blood cells, but the CPP carrier destroys the very cells it needs to penetrate. This highlights the need for systematic toxicity assessment in the CPP field and may redirect malaria peptide research toward alternative delivery strategies like nanoparticles or liposomes.

The study focused on aminoquinoline antimalarials (chloroquine, primaquine) specifically, so the hemolysis finding may not apply to other drug classes conjugated to CPPs. The range of cell-penetrating peptides tested was limited. In vivo antimalarial activity and hemolysis were not assessed — the findings are based on in vitro assays. The mechanism of hemolysis (whether driven by the peptide, the drug, or the conjugation chemistry) was not fully dissected.